US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States

Saran, Rajiv; Robinson, Bruce M.; Abbott, Kevin C.; Agodoa, Lawrence Y.; Bragg‐Gresham, Jennifer L.; Balkrishnan, Rajesh; Bhave, Nicole M.; Dietrich, Xue; Ding, Zhechen; Eggers, Paul W.; Gaipov, Abduzhappar; Gillen, Daniel L.; Gipson, Debbie S.; Gu, Haoyu; Guro, Paula; Haggerty, Diana; Han, Yun; He, Kevin; Herman, William H.; Heung, Michael; Hirth, Richard A.; Hsiung, Jui-Ting; Hutton, David; Inoue, Aya; Jacobsen, Steven J.; Jin, Yan; Kalantar-Zadeh, Kamyar; Kapke, Alissa; Kleine, Carola-Ellen; Kövesdy, Csaba P.; Krueter, William; Kurtz, Vivian; Li, Yiting; Liu, Sai; Marroquin, Maria; McCullough, Keith; Molnár, Miklós; Modi, Zubin; Montez‐Rath, Maria E.; Moradi, Hamid Reza; Morgenstern, Hal; Mukhopadhyay, Purna; Nallamothu, Brahmajee; Nguyen, Danh V.; Norris, Keith C.; O’Hare, Ann M.; Obi, Yoshitsugu; Park, Christina; Pearson, Jeffrey; Pisoni, Ronald L.; Potukuchi, Praveen K.; Repeck, Kaitlyn; Rhee, Connie M.; Schaubel, Douglas E.; Schrager, Jillian; Selewski, David T.; Shamraj, Ruth; Shaw, Sally F.; Shi, Jiaxiao; Shieu, Monica; Sim, John J.; Soohoo, Melissa; Steffick, Diane; Streja, Elani; Sumida, Keiichi; Tamura, Manjula Kurella; Tilea, Anca; Turf, Megan; Wang, Dongyu; Weng, Wenjing; Woodside, Kenneth J.; Wyncott, April; Xiang, Jie; Xin, Xin; Yin, Maggie; You, Amy S.; Zhang, Xiaosong; Zhou, Hui; Shahinian, Vahakn B.

doi:10.1053/j.ajkd.2019.01.001

Cited by 737 publications

(591 citation statements)

References 0 publications

Supporting

Mentioning

554

Contrasting

Unclassified

Order By: Relevance

“…The increasing prevalence of end‐stage renal disease (ESRD) and its associated morbidity and mortality represent an important public health problem worldwide . According to the US Renal Data System (USRDS) 2018 Annual Data Report, in the United States, the number of new cases registered as ESRD was 124 675 and the total number of cases reached 726 331 in 2016; meanwhile, the prevalence of ESRD is continuing to rise . The ESRD cases could rise sharply over the next few decades, and the estimated global number of people receiving renal replacement therapy would be more than double to 5.439 million in 2030 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of infections and antimicrobial use among hemodialysis outpatients: A prospective multicenter study

Zhang

et al. 2020

Seminars in Dialysis

View full text Add to dashboard Cite

Hemodialysis patients are vulnerable to infectious diseases and frequent receipt of antimicrobial agents. The aim of this study was to describe the prevalence and characteristics of infections and antimicrobials use among hemodialysis outpatients. We utilized the dialysis event surveillance protocol developed by the National Healthcare Safety Network to conduct a prospective multicenter study in Anhui, China. A total of 41 dialysis centers involving 7393 outpatients were included. Fistula was the most common type of vascular access (85.3%), followed by tunneled central line (12.7%), and non‐tunneled central line (1.2%). There were 118 dialysis events with an overall pooled events rate of 1.60 per 100 patient‐months. Intravenous antimicrobial start, positive blood culture, and pus, redness, or increased swelling at the vascular access site were detected at rates of 0.91, 0.23, and 0.46 per 100 patient‐months, respectively. The prevalence of dialysis events was commonly higher in patients with a central line, and lower in patients with a fistula. Hemodialysis outpatients also had the noteworthy risks of nonaccess infections. Older age, female gender, and having a central line were associated with the increased risk of dialysis events. Findings recommend that regular monitoring and improvement strategies are warranted in management of infections among hemodialysis outpatients.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of infections and antimicrobial use among hemodialysis outpatients: A prospective multicenter study

Zhang

et al. 2020

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…While these studies identified therapeutic targets and disease endophenotypes, they were limited to the evaluation of glomerular diseases in routine biopsies and the analysis of tissue compartments consisting of a multitude of interacting cell types (9). Recognizing this opportunity, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiated the Kidney Precision Medicine Project (KPMP) with the explicit goal to bring the biomedical advances of tissue level disease process mapping to the two most devastating renal diseases, chronic kidney disease (CKD) and acute kidney injury (AKI), with a prevalence as high as 14% (37 million people) for CKD (10). In a sequential process, KPMP is establishing a framework to ethically and safely obtain research kidney biopsies from study participants with CKD and AKI, using a sophisticated tissue acquisition protocol specifically tailored to enable downstream emerging molecular genome scale analyses at tissue and cell level resolution.…”

Section: Introductionmentioning

confidence: 99%

A Multimodal and Integrated Approach to Interrogate Human Kidney Biopsies with Rigor and Reproducibility: The Kidney Precision Medicine Project

El-Achkar

Eadon

Menon

et al. 2019

Preprint

View full text Add to dashboard Cite

Comprehensive and spatially mapped molecular atlases of organs at a cellular level are a critical resource to gain insights into pathogenic mechanisms and therapies tailored to the disease of each patient. Obtaining rigorous and reproducible results from disparate methods and at different sites to interrogate biomolecules at a single cell level or in 3-dimensional (3D) space is a significant challenge that can be a futile exercise if not well controlled. The Kidney Precision Medicine Project (KPMP) is an endeavor to generate 3D molecular atlases of healthy and diseased kidney biopsies using multiple state-of-the-art OMICS and imaging technologies across several institutions. We describe a pipeline for generating a reliable and authentic single cell/region 3D molecular atlas of human adult kidney with emphasis on quality assurance, quality control, validation and harmonization across different OMICS and imaging methods. Our “follow the tissue” approach encompasses sample procurement to data generation, analysis, data sharing, while standardizing, and harmonizing procedures at sample collection, processing, storage and shipping. We provide key features of preanalytical parameters, bioassays, post analyses, reference standards and data depositions. A pilot experiment from a common source tissue processed and analyzed at different institutions was executed to identify potential sources of variation, feasibility of multimodal analyses and unique and redundant features of the macromolecules being characterized by each technology. An important outcome was identification of limitations and strengths of the different technologies, and how composite information can be leveraged for clinical application. A peer review system was established to critically review quality control measures and the reproducibility of data generated by each technology before granting approval to work on clinical biopsy specimens. This unique pipeline establishes a process that economizes the use of valuable biopsy tissue for multi-OMICS and imaging analysis with stringent quality control to ensure rigor and reproducibility of results and which can serve as a model for similar personalized medicine projects.Author ContributionsMTE, RM, BBL, TS, TA, AS, SP, CRA, DD, EAO, SW, GZ, MJ and KD performed the ground work for the quality control group, wrote the KPMP TIS manual of procedures and generated figures. HH, JZ, RS, RM, TS, EAO, MTE, TME, PH, SP, MK, ZL and SJ generated the initial working reference marker list. CEA, TME, JBH, JL, MK and SJ led the Pilot 1 protocol. TME, VD, LB, JG, CEA, ZL, SJ and JBH developed the pathology QC tissue qualification and tissue processing criteria. JBH organized and executed the Pilot tissue collection and distribution. JC designed the SpecTrack system. CP prepared and organized the TIS manual of procedures and performed data organization services. YH led ontology development for QC metadata and knowledge standardization. BS and EA organized data integration efforts and data authentication in the data hub. KS and MS led the OMICS discussion group. SJ led the quality control group. TME and CEA led the tissue processing group. MTE and SJ led the Molecular and Pathology Integration group. MTE and SJ conceived and led the TISAC process. RI, OGT KZ, ZL, PH, BR, PCD, KS, MS, JBH, CEA, LB, JG, TME, MK and SJ conceived the integrated TIS pipeline and QC vision. TME and SJ wrote the initial draft of the paper. All authors contributed to the writing and editing of the manuscript.

show abstract

“…New therapies to arrest chronic kidney disease (CKD) progression and prevent end‐stage kidney failure are urgently needed as the cost of treating these patients approaches a staggering $114 billion/year in the United States (Saran et al, ). A leading cause of CKD is injury and loss of glomerular podocytes, highly specialized and differentiated epithelial cells that are an integral component of the glomerular filtration barrier (Matsusaka et al, ; Wharram et al, ).…”

Section: Introductionmentioning

confidence: 99%

Optimized nonviral gene delivery for primary urinary renal progenitor cells to enhance cell migration

Liu

Johnson

Jain

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

Progressive loss of glomerular podocytes during kidney disease leads to irreversible kidney failure, and is exacerbated by the fact that podocytes are terminally differentiated epithelial cells and unable to proliferate. Regeneration of lost podocytes must therefore derive from nonpodocyte sources. Human urine‐derived renal progenitor cells (uRPCs) are attractive podocyte progenitors for cell therapy applications due to their availability from patient urine and ability to migrate to injured glomeruli and differentiate into de novo podocytes after intravenous administration. Because gene delivery has emerged as an important strategy to augment the functionality and survival of cell therapies prior to injection, in this work we optimized nonviral gene delivery conditions (cell density, DNA dose, % FBS, and transfection material composition) to primary uRPCs. Using the cationic polymer‐peptide conjugate VIPER for gene delivery and the Sleeping Beauty transposon/transposase constructs for gene integration, we optimized transfection parameters to achieve efficient transgene expression (up to 55% transfected cells) and stable transgene expression (>65% integration efficiency) lasting up to 10 days. With these methods, we transfected uRPCs to overexpress CXCR4, an important chemokine receptor that mediates uRPC migration to the kidneys after intravenous injection, and demonstrate that CXCR4‐uRPCs exhibit enhanced migration compared to mock‐transfected cells.

show abstract

US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States

Cited by 737 publications

References 0 publications

Prevalence of infections and antimicrobial use among hemodialysis outpatients: A prospective multicenter study

Prevalence of infections and antimicrobial use among hemodialysis outpatients: A prospective multicenter study

A Multimodal and Integrated Approach to Interrogate Human Kidney Biopsies with Rigor and Reproducibility: The Kidney Precision Medicine Project

Optimized nonviral gene delivery for primary urinary renal progenitor cells to enhance cell migration

Contact Info

Product

Resources

About